Genaissance Enters Pharmacogenomic Collaboration with Otsuka
News Sep 30, 2005
Genaissance Pharmaceuticals, Inc. has announced that it has entered into a pharmacogenomic research collaboration with Otsuka Pharmaceutical Co., Ltd.
Under the terms of the agreement, Genaissance will apply its HAP™ Technology with the goal of identifying genetic markers related to drug response.
Genaissance and Otsuka will be co-owners of the intellectual property that results from the collaboration and both companies will be eligible to receive royalties on revenues generated from diagnostic products resulting from the collaboration.
"We are very pleased that we will be collaborating with Otsuka," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals.
"We believe this agreement is another indication that pharmacogenomics is becoming an important tool for drug development."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE